HRH1 and irritable bowel syndrome: Ebastine [ClinicalTrials.gov: NCT01908465 (phase 4)], the HRH1-antagonist, was found to reduce abdominal pain in a state-of-the-art study on IBS patients (Wouters et al., 2016a).